PHILADELPHIA, Sept. 16, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the “Company”) today announced that its Board of Directors has just approved up to $4.4 Million (U.S.) for full engineering studies, capital improvements, system upgrades, and introduction of building management systems to enhance production of three products: Alferon N(R) (its FDA licensed biologic), Alferon LDO and Ampligen(R). Alferon LDO and Ampligen(R) (Poly I : Poly C12U) are experimental therapeutics being developed for multiple clinical indications including prevention, prophylaxis and treatment of both seasonal and pandemic influenza.
